Fifth Third Bancorp Buys 11,183 Shares of Spyre Therapeutics, Inc. $SYRE

Fifth Third Bancorp lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 71.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,821 shares of the company’s stock after purchasing an additional 11,183 shares during the period. Fifth Third Bancorp’s holdings in Spyre Therapeutics were worth $2,388,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in Spyre Therapeutics by 192.6% in the 1st quarter. Bank of America Corp DE now owns 1,228,093 shares of the company’s stock worth $61,945,000 after acquiring an additional 808,366 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company’s stock valued at $190,826,000 after purchasing an additional 714,000 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Spyre Therapeutics during the third quarter valued at approximately $53,349,000. ADAR1 Capital Management LLC lifted its holdings in Spyre Therapeutics by 893.6% during the first quarter. ADAR1 Capital Management LLC now owns 338,323 shares of the company’s stock valued at $17,065,000 after purchasing an additional 304,272 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Spyre Therapeutics in the second quarter worth approximately $21,768,000. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Trading Down 4.3%

NASDAQ SYRE opened at $93.47 on Friday. Spyre Therapeutics, Inc. has a 12 month low of $23.01 and a 12 month high of $110.64. The stock has a market cap of $8.88 billion, a PE ratio of -34.11 and a beta of 3.24. The stock’s 50 day moving average is $92.28 and its 200 day moving average is $77.91.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). On average, analysts forecast that Spyre Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on SYRE shares. BTIG Research reissued a “buy” rating and issued a $121.00 price objective on shares of Spyre Therapeutics in a research note on Monday, October 19th. UBS Group initiated coverage on shares of Spyre Therapeutics in a research note on Sunday, October 11th. They set a “buy” rating and a $120.00 target price on the stock. Deutsche Bank lowered their target price on shares of Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, August 26th. Wells Fargo & Company upped their target price on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, Guggenheim increased their price target on Spyre Therapeutics from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.53.

Get Our Latest Analysis on Spyre Therapeutics

Insider Activity at Spyre Therapeutics

In other Spyre Therapeutics news, insider Heidy King-Jones sold 28,933 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $91.03, for a total value of $2,633,770.99. Following the sale, the insider owned 2,845 shares in the company, valued at $258,980.35. The trade was a 91.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $92.01, for a total transaction of $1,380,150.00. Following the transaction, the chief executive officer directly owned 537,540 shares of the company’s stock, valued at $49,459,055.40. This trade represents a 2.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 138,064 shares of company stock valued at $12,349,518. Corporate insiders own 15.69% of the company’s stock.

Spyre Therapeutics Company Profile

(Free Report)

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Further Reading

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).

Institutional Ownership by Quarter for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.